Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant With Ribociclib vs Physician's Choice in HR+/HER2- Metastatic Breast Cancer
NCT06849947Phase 2Not yet recruiting
- Start
- Feb 2026
- Primary completion
- Jun 2031
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of ribociclib in breast cancer. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06849947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06849947.